Selank Research

Selank research occupies a particular niche in neuropeptide pharmacology: the study of a small synthetic peptide developed as a stable, anxiolytic-type regulator. Selank is a synthetic heptapeptide based on the natural immunopeptide tuftsin. Much of the interest in it concerns how it interacts with GABAergic signaling and related systems in the brain. This article summarizes preclinical findings on Selank and anxiolytic peptide biology. It covers its structure, the mechanisms proposed for it, and the cell and animal evidence reported so far. It states whether each finding comes from a cell or an animal model, and it describes what research has investigated rather than any outcome a reader should expect. Selank is a research compound and is not characterized here for human use.

What Selank is

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, built from the endogenous tetrapeptide tuftsin. Tuftsin is the short Thr-Lys-Pro-Arg fragment derived from the heavy chain of immunoglobulin G. Selank extends that fragment at the C-terminus by three natural amino acids, Pro-Gly-Pro. That extension was added specifically to improve the molecule's metabolic stability and to give it a longer duration than the rapidly degraded parent peptide.

Selank was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Selank derives from tuftsin, an immunomodulatory peptide, so it carries both neuropeptide and immune-related activities. That dual character is part of what makes its pharmacology complex.

The GABAergic angle

The link between Selank and GABAergic signaling is the most actively studied aspect of its mechanism. Volkova and colleagues reported in 2016 that administration of Selank changed the mRNA levels of several genes involved in GABAergic neurotransmission in the rat frontal cortex. That work was done in living animals, and the pattern of change correlated with the pattern produced by GABA itself. The authors concluded that one of Selank's possible molecular mechanisms is allosteric modulation of the GABAergic system. This is an in vivo (rat) finding, and a proposed mechanism rather than a confirmed one.^[1]

A follow-up study by Filatova and colleagues in 2017 tested the same question in cultured human IMR-32 neuroblastoma cells. Selank alone produced no change in the mRNA levels of the GABAergic genes studied. When it was combined with GABA, it suppressed most of the expression changes that GABA produced on its own. Taken together, these in vitro results suggest that Selank does not act directly on GABAergic gene transcription in isolated cells. The same in vitro results suggest it may instead modify the interaction of GABA with its receptors, which is consistent with the whole-animal effects being indirect.^[2] The two studies illustrate that the GABAergic mechanism of Selank is plausible but not fully resolved.

Vyunova and colleagues added a direct binding result in 2018. In radioligand binding assays on plasma membranes isolated from rat brain cells, Selank acted as a positive allosteric modulator of [3H]GABA binding. In those same assays it also blocked the modulatory activity of diazepam and olanzapine, and the peptide's binding site appeared distinct from the benzodiazepine binding site, though potentially partially overlapping with it.^[6]

Selank mechanism of action beyond GABA

A second, better-characterized strand concerns the endogenous opioid system. Zozulya and colleagues reported in 2001 that Selank inhibits enkephalin-degrading enzymes in vitro, dose-dependently slowing the enzymatic hydrolysis of plasma enkephalin and doing so more potently than the reference peptidase inhibitors bacitracin and puromycin.^[3] By slowing enkephalin breakdown, the peptide is thought to prolong endogenous enkephalin signaling rather than acting directly on opioid receptors.

Animal data support this strand. Sokolov and colleagues showed in 2002 that Selank produced an anxiolytic-type effect in the open-field test in a mouse strain prone to anxiety-like behavior. The peptide also increased the half-life of plasma enkephalin in that strain, whereas a different strain showed neither response.^[4]

A further strand concerns neurotrophic signaling: Inozemtseva and colleagues reported in 2008 that intranasal Selank regulated brain-derived neurotrophic factor (BDNF) expression in the rat hippocampus in vivo.^[5] That finding adds a neurotrophic dimension to the peptide's actions. Changes in monoamine-related gene expression were also reported in the rat gene-expression work above, indicating that Selank acts across more than one neurotransmitter system.^[1]

Preclinical behavioral findings

Behavioral pharmacology in rodents has characterized Selank as an anxiolytic-type compound with a profile distinct from classical sedatives. In the open-field test, Sokolov and colleagues reported an anxiolytic-type effect in anxiety-prone BALB/c mice at 100 μg/kg, with no corresponding behavioral change in C57Bl/6 mice.^[4]

The 2001 enzymology report characterizes Selank as attenuating behavioral anxiety reactions without the side effects typical of most anxiolytics, though that paper measured enzyme activity rather than behavior.^[3] Cognitive endpoints have also been examined: Semenova and colleagues reported in 2007 that Selank affected cognitive processes in rats following early-life damage to the brain's catecholamine system.^[7] These are animal model results and should not be extrapolated to human outcomes.

Human research context

The directly relevant mechanistic and behavioral evidence on Selank is preclinical, drawn from cell and animal studies. Selank has been investigated in human clinical research in Russia, where a nasal formulation is registered. The 2001 study above also included a human biochemical observation: patients with generalized anxiety showed a shortened enkephalin half-life and reduced blood enkephalinase activity.^[3] That was the biochemical backdrop against which Selank's enzyme-inhibiting action was proposed. That clinical work is distinct from the research-grade compound discussed here, and no personal outcome should be inferred from it.

Limitations and research directions

Several limitations shape how this literature should be read. A large share of the work originates from a small network of affiliated Russian institutes, and much of it is published in Russian-language journals, which limits independent replication. The proposed mechanisms, GABAergic, enkephalinergic, neurotrophic and monoaminergic, are multiple and not fully reconciled. The contrast between the in vivo and in vitro GABAergic findings shows that the picture is still being worked out.

Conclusion

Selank is best understood as a metabolically stabilized, tuftsin-derived heptapeptide studied as an anxiolytic-type neuropeptide. Its preclinical profile points to a multi-target mechanism, with action on the GABAergic system proposed but not fully resolved. The effect on enkephalin-degrading enzymes is better characterized, and both sit alongside behavioral data in animal models.

References

1. 1

   Volkova A, Shadrina M, Kolomin T, Andreeva L, Limborska S, Myasoedov N, Slominsky P. Selank administration affects the expression of some genes involved in GABAergic neurotransmission. Front Pharmacol. 2016;7:31. PMID 26924987.
2. 2

   Filatova E, Kasian A, Kolomin T, Rybalkina E, Alieva A, Andreeva L, et al. GABA, Selank, and olanzapine affect the expression of genes involved in GABAergic neurotransmission in IMR-32 cells. Front Pharmacol. 2017;8:89. PMID 28293190.
3. 3

   Zozulya AA, Kost NV, Sokolov OYu, Gabaeva MV, Grivennikov IA, Andreeva LN, et al. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bull Exp Biol Med. 2001;131(4):315-317. PMID 11550013.
4. 4

   Sokolov OYu, Meshavkin VK, Kost NV, Zozulya AA. Effects of Selank on behavioral reactions and activities of plasma enkephalin-degrading enzymes in mice with different phenotypes of emotional and stress reactions. Bull Exp Biol Med. 2002;133(2):133-135. PMID 12432865.
5. 5

   Inozemtseva LS, Karpenko EA, Dolotov OV, Levitskaya NG, Kamensky AA, Andreeva LA, et al. Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Dokl Biol Sci. 2008;421:241-243. PMID 18841804.
6. 6

   Vyunova TV, Andreeva L, Shevchenko K, Myasoedov N. Peptide-based anxiolytics: the molecular aspects of heptapeptide Selank biological activity. Protein Pept Lett. 2018;25(10):914-923. PMID 30255741.
7. 7

   Semenova TP, Kozlovskaya MM, Zakharova NM, Kozlovskii II, Zuikov AV. Effect of selank on cognitive processes after damage inflicted to the cerebral catecholamine system during early ontogeny. Bull Exp Biol Med. 2007;144(5):689-691. PMID 18683497.